Biltmore Family Office, LLC Gilead Sciences, Inc. Transaction History

Biltmore Family Office, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 05, 2020	SELL	$72.34 - $84.0 $323,070 - $375,144	-4,466 Closed	0 $0
Q1 2020 May 08, 2020	SELL	$62.63 - $80.22 $118,871 - $152,257	-1,898 Reduced 29.82%	4,466 $334,000
Q4 2019 Feb 05, 2020	BUY	$61.62 - $67.78 $95,819 - $105,397	1,555 Added 32.34%	6,364 $414,000
Q3 2019 Oct 16, 2019	SELL	$62.51 - $69.0 $39,881 - $44,022	-638 Reduced 11.71%	4,809 $305,000
Q2 2019 Jul 31, 2019	SELL	$61.87 - $69.38 $38,916 - $43,640	-629 Reduced 10.35%	5,447 $368,000
Q1 2019 Apr 12, 2019	BUY	$62.53 - $70.05 $13,756 - $15,411	220 Added 3.76%	6,076 $395,000
Q4 2018 Feb 13, 2019	BUY	$60.54 - $79.0 $92,686 - $120,949	1,531 Added 35.4%	5,856 $366,000
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $23,673 - $28,860	325 Added 8.13%	4,325 $326,000
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $284,600 - $334,080	4,000	4,000 $287,000

1,923

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Biltmore Family Office, LLC, based on Form 13F filings with the SEC.

Stay updated on Biltmore Family Office, LLC with notifications on news.